

The effect of Dr Allen's Device and Thermobalancing Therapy on erectile dysfunction in men with chronic prostate diseases

Submission date 17/12/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 09/01/2023	Overall study status Completed	<input checked="" type="checkbox"/> Protocol
Last Edited 20/05/2024	Condition category Urological and Genital Diseases	<input checked="" type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostate enlargement (BPE) – also known as an enlarged prostate or benign prostatic hyperplasia (BPH) – are common health conditions among men. The prevalence of histologically diagnosed BPE increases from 8% in men aged 40 years old to 40-50% in men aged 51 to 60 years old, to over 80% in men older than age 80 years. These health problems are often accompanied by erectile dysfunction (ED). It has been confirmed that novel thermobalancing therapy with Dr Allen's Device for Prostate Treatment reduces prostate inflammation in patients with CP/CPPS, decreases the size of benign prostate enlargement, and eases lower urinary tract symptoms (LUTS) associated with BPE. Also, this treatment has a positive effect on the health-related quality of life (HRQoL) in men with CP/CPPS and BPE. Moreover, no complications associated with the use of Dr Allen's Device have ever been observed in patients with BPH and chronic prostatitis. Many studies show that commonly used medications and surgeries for CP/CPPS and BPE have a negative effect on the HRQoL, and lead to ED. Standard treatment options with drugs can cause side effects, especially in long-term use. Surgical interventions are associated with irreversible complications. Most of these side effects and complications affect erectile and sexual function causing emotional problems and depression. Solving these problems is, therefore, extremely important for men's long-term health and well-being. Therefore, this study will evaluate thermobalancing therapy for ED and HRQoL in men with CP/CPPS and BPE. It is anticipated that Dr Allen's Device and thermobalancing therapy will treat ED and improve erectile function, reduce the size of the inflamed or enlarged prostate gland, reduce urinary symptoms, and improve the quality of life in men with chronic prostatitis (CP/CPPS) or benign prostate enlargement (BPE). The findings may allow us to recommend this novel out-of-hospital treatment as a new safe solution for ED.

Who can participate?

Men aged between 40 and 55 years old with ED due to CP/CPPS or BPH

What does the study involve?

Thermobalancing therapy improves blood circulation in the affected prostate gland by means of local temperature regulation for a prolonged period of time. It is achieved with the continuous use of the wearable Dr Allen's Device. Dr Allen's Device for Prostate Treatment is designed as a soft belt with a thermoelement made from a special wax-based material. It maintains the required temperature when retained on the body; it needs to be placed correctly with the thermoelement covering the coccyx area of the back. A total of 100 participants will be recruited for the study: 50 participants will be placed in the treatment group and 50 participants will be placed in the control group. Every participant will be randomly assigned to either the treatment group or the control group. Thermobalancing therapy with Dr Allen's Device will be used as a monotherapy. Patients in the treatment group will use Dr Allen's Device. Patients in the control group will be under watchful waiting and will not receive treatment with Dr Allen's Device. Every participant will be assessed 3 times during the study: before the start of the treatment, and 3 and 6 months after the start of the treatment.

What are the possible benefits and risks of participating?

The benefits of participating in this study include receiving a non-invasive and totally safe treatment with thermobalancing therapy and Dr Allen's Device designed to improve erectile function and overall wellbeing in men with chronic prostatic diseases. Dr Allen's Device provides an at-home treatment, without the need for hospitalisation or any other medical interventions. Dr Allen's Device is easy to use and does not impede daily activities of its user. There are no risks associated with the use of Dr Allen's Device, which is a Class 1 Medical Device.

Where is the study run from?

Fine Treatment (UK)

When is the study starting and how long is it expected to run for?

June 2022 to November 2023

Who is funding the study?

Fine Treatment (UK)

Who is the main contact?

Fine Treatment, info@finetreatment.com (UK)

Contact information

Type(s)

Principal investigator

Contact name

Dr Simon Allen

ORCID ID

<https://orcid.org/0000-0003-2273-8439>

Contact details

Fine Treatment
13 Station Road
Borough Green
Sevenoaks, Kent

United Kingdom
TN15 8ES
+44 (0)7958878300
info@finetreatment.com

Type(s)

Public

Contact name

Dr Ariana Adjani

ORCID ID

<https://orcid.org/0000-0001-7367-2658>

Contact details

Senior Researcher
Fine Treatment
13 Station Road
Borough Green
Sevenoaks, Kent
United Kingdom
TN15 8ES
+44 (0)7958878300
ariana.adjani@finetreatment.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

CT-5-ED-TT-DAD

Study information

Scientific Title

Investigation of the effect of Thermobalancing therapy and Dr Allen's Device for Prostate Treatment on erectile dysfunction, prostate volume, and health-related quality of life in men with chronic prostatitis/chronic pelvic pain syndrome and benign prostate enlargement

Acronym

TT-DAD-ED-CP-BPE

Study objectives

The out-of-hospital treatment with Thermobalancing therapy and Dr Allen's Device for Prostate Treatment is expected to improve erectile function, reduce the size of the inflamed or enlarged prostate gland, reduce urinary symptoms, and improve health-related quality of life in men with chronic prostatitis/chronic pelvic pain syndrome and benign prostate enlargement.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 06/07/2022, the Ethics Review Committee of the Government College University Faisalabad (Kotwali Road, Faisalabad, Punjab, 38000, Pakistan; +92(0)419200876; drmharsool@gcuf.edu.pk), ref: GCUF/ERC/110

Study design

Single-centre prospective interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Treatment for erectile dysfunction in patients with benign prostate enlargement or chronic prostatitis/chronic pelvic pain syndrome

Interventions

The purpose of this clinical trial is to investigate the effect of the out-of-hospital treatment with Thermobalancing therapy and Dr Allen's Device for Prostate Treatment on erectile dysfunction, the size of the inflamed or enlarged prostate gland, urinary symptoms, and health-related quality of life (HRQoL) in men with ED linked to CP/CPPS or BPE.

Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) and benign prostate enlargement (BPE) – also known as an enlarged prostate or benign prostatic hyperplasia (BPH) – are common health conditions among men. CP/CPPS affects 8.2% of men. The prevalence of histologically diagnosed BPE increases from 8% in men aged 40, to 40-50% in men aged 51 to 60, to over 80% in men older than age 80. These health problems are often accompanied by erectile dysfunction (ED).

It has been confirmed that novel Thermobalancing therapy and Dr Allen's Device for Prostate Treatment reduce prostate inflammation in patients with CP/CPPS, decrease the size of benign prostate enlargement, and ease lower urinary tract symptoms (LUTS) associated with BPE. Also, this treatment has a positive impact on the health-related quality of life in men with CP/CPPS and BPE. Moreover, no complications associated with the use of Dr Allen's Device have ever been observed in patients with BPH and chronic prostatitis.

Many studies show that commonly used medications and surgeries for CP/CPPS and BPE have a negative effect on the quality of life, and lead to ED. Standard treatment options with drugs can cause side effects, especially in long-term use. Surgical interventions are associated with irreversible complications. Most of these side effects and complications affect erectile and sexual function causing emotional problems and depression. Solving these problems is, therefore, extremely important for men's long-term health and well-being.

Therefore, new research on Thermobalancing therapy for ED and health-related quality of life in men with CP/CPPS and BPE is needed.

A total of 100 participants will be recruited for the study: 50 participants with ED due to CP /CPPS and 50 participants with ED due to BPH. Every participant in each of these 2 groups will be randomly assigned to either the treatment groups or the control groups in equal numbers of 25 participants in each group.

Thermobalancing therapy with Dr Allen's Device will be used as a monotherapy. Every participant in the treatment groups will be investigated during the clinical trial 3 times: before the start of the treatment, 3 and 6 months after the start of the treatment. Every participant in the control groups will be investigated during the clinical trial also 3 times: at the start of the observation period, 3 and 6 months later.

Patients in the treatment groups will use Dr Allen's Device. Patients in the control groups will be placed under watchful waiting and will not receive treatment with Dr Allen's Device. The data collected from the treatment groups will be compared to the control groups in watchful waiting. No other interventions, including medications and surgical procedures, will be used.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Dr Allen's Device

Primary outcome(s)

The following outcomes will be assessed three times in total, before, during and at the end of the treatment period:

1. Severity of erectile dysfunction measured using the International Index of Erectile Function (IIEF-5) Questionnaire
2. Volume of the prostate gland measured using ultrasound
3. Severity of urinary symptoms measured using the AUA Symptom Score Questionnaire

Key secondary outcome(s)

The following outcomes will be assessed three times in total, before, during and at the end of the treatment period:

1. Health-related quality of life (HRQoL) measured using the Short Form Survey Instrument (SF-36)
2. Serum levels of prostate-specific antigen, total testosterone, and 17 β -estradiol (E2) measured using blood samples and standard techniques

Completion date

01/11/2023

Eligibility

Key inclusion criteria

Aged between 40 and 55 with ED due to CP/CPPS or BPH

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Total final enrolment

100

Key exclusion criteria

1. Previous prostate surgeries
2. Infectious diseases
3. Severe comorbidities, such as cancer, heart failure, and end-stage chronic diseases
4. Cognitive impairment
5. Mental illness

Date of first enrolment

12/01/2023

Date of final enrolment

01/04/2023

Locations

Countries of recruitment

Pakistan

Study participating centre

Government College University Faisalabad

Kotwali Road

Faisalabad

Pakistan

38000

Sponsor information

Organisation

Fine Treatment (United Kingdom)

ROR

Funder(s)

Funder type

Industry

Funder Name

Fine Treatment (United Kingdom)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Simon Allen, Director, Fine Treatment, info@finetreatment.com.

- The type of data that will be shared: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
- Dates of availability: Beginning 9 months and ending 3 years following article publication.
- Whether consent from participants was required and obtained: Informed Consent will be obtained from all participants by signing the Informed Consent form before any trial specific procedures are performed.
- Comments on data anonymization: Data will be anonymised.
- Any ethical or legal restrictions: Data will be provided upon request for research purposes only.
- Any additional comments: Data will be made available to researchers who provide a methodologically sound proposal.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 1.0	01/06/2022	05/01/2023	No	No
Statistical Analysis Plan	version 1.0	01/06/2022	05/01/2023	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes